BioNTech Partner's Drug IND Application Placed on Clinical Hold
Ticker: BNTX · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: clinical-hold, fda, partnership, drug-development
Related Tickers: BNTX
TL;DR
FDA puts clinical hold on BioNTech partner's drug ONC-390 IND, halting US trials.
AI Summary
BioNTech SE announced on December 13, 2024, that its partner OncoC4, Inc. has been informed by the U.S. Food and Drug Administration (FDA) regarding the investigational new drug (IND) application for ONC-390. The FDA has placed a clinical hold on the IND application, meaning further clinical trials for ONC-390 cannot proceed in the United States at this time.
Why It Matters
This clinical hold by the FDA prevents OncoC4 from initiating U.S. trials for ONC-390, potentially delaying its development and market entry for the drug.
Risk Assessment
Risk Level: medium — A clinical hold on an IND application signifies regulatory hurdles that could delay or halt the drug's development, impacting BioNTech's partnership and potential future revenue.
Key Players & Entities
- BioNTech SE (company) — Registrant and partner's collaborator
- OncoC4, Inc. (company) — BioNTech's partner
- ONC-390 (drug) — Investigational drug
- U.S. Food and Drug Administration (company) — Regulator
FAQ
What is the status of the IND application for ONC-390?
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on the IND application for ONC-390.
Who informed BioNTech SE about the clinical hold?
BioNTech SE was informed by its partner, OncoC4, Inc.
What is the implication of a clinical hold?
A clinical hold means that further clinical trials for the drug cannot proceed in the United States at this time.
What is the name of the investigational drug?
The investigational drug is named ONC-390.
When was this information filed with the SEC?
This Form 6-K was filed on December 13, 2024.
Filing Stats: 832 words · 3 min read · ~3 pages · Grade level 16 · Accepted 2024-12-13 16:01:12
Filing Documents
- form6-kbnt316holdlift13dec.htm (6-K) — 18KB
- 0001776985-24-000098.txt ( ) — 19KB
Forward-Looking Statements
Forward-Looking Statements This statement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the next steps in the PRESERVE-003 trial and other clinical trials of BNT316ONC-392 the potential that BNT316ONC-392 may help to preserve T cell activity and enhance anti-tumor activity and the potential efficacy and safety of BNT316ONC-392. In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this statement are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Quarterly Report on Form 6-K for the period ended September 30, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at httpswww.sec.gov. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this statement in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf